Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg Sells 14,611 Shares

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 14,611 shares of Outset Medical stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $0.90, for a total value of $13,149.90. Following the completion of the sale, the chief executive officer now directly owns 880,969 shares in the company, valued at $792,872.10. This represents a 1.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 21st, Leslie Trigg sold 65,236 shares of Outset Medical stock. The shares were sold at an average price of $0.80, for a total value of $52,188.80.
• On Monday, January 13th, Leslie Trigg sold 33,227 shares of Outset Medical stock. The stock was sold at an average price of $0.81, for a total value of $26,913.87.
• On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The stock was sold at an average price of $1.29, for a total transaction of $13,192.83.

Outset Medical Stock Up 3.5 %

OM opened at $0.94 on Thursday. The company has a debt-to-equity ratio of 4.12, a quick ratio of 5.04 and a current ratio of 6.49. The company has a market cap of $50.48 million, a price-to-earnings ratio of -0.34 and a beta of 2.01. Outset Medical, Inc. has a one year low of $0.44 and a one year high of $5.22. The business’s fifty day moving average is $0.96 and its two-hundred day moving average is $0.85.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Outset Medical had a negative return on equity of 164.92% and a negative net margin of 122.84%. Analysts anticipate that Outset Medical, Inc. will post -2.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Huntington National Bank lifted its holdings in Outset Medical by 46.2% in the 3rd quarter. Huntington National Bank now owns 63,306 shares of the company’s stock valued at $43,000 after purchasing an additional 20,000 shares in the last quarter. National Bank of Canada FI lifted its stake in shares of Outset Medical by 79.2% during the third quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after buying an additional 23,164 shares during the period. Two Sigma Securities LLC boosted its position in Outset Medical by 190.0% during the fourth quarter. Two Sigma Securities LLC now owns 42,477 shares of the company’s stock worth $47,000 after acquiring an additional 27,830 shares during the last quarter. XTX Topco Ltd purchased a new stake in Outset Medical in the 4th quarter worth approximately $50,000. Finally, Two Sigma Investments LP raised its holdings in Outset Medical by 36.0% in the 4th quarter. Two Sigma Investments LP now owns 488,602 shares of the company’s stock valued at $542,000 after acquiring an additional 129,334 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research note on Tuesday, January 7th.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.